James A Rogers
Overview
Explore the profile of James A Rogers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Sanghavi K, Ribbing J, Rogers J, Ahmed M, Karlsson M, Holford N, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Apr;
13(5):710-728.
PMID: 38566433
Modeling the relationships between covariates and pharmacometric model parameters is a central feature of pharmacometric analyses. The information obtained from covariate modeling may be used for dose selection, dose individualization,...
3.
Wiens M, French J, Rogers J
CPT Pharmacometrics Syst Pharmacol
. 2023 Nov;
13(2):187-191.
PMID: 37984457
No abstract available.
4.
Rogers J, Maas H, Perez Pitarch A
CPT Pharmacometrics Syst Pharmacol
. 2022 Nov;
12(1):27-40.
PMID: 36385744
As formal causal inference begins to play a greater role in disciplines that intersect with pharmacometrics, such as biostatistics, epidemiology, and artificial intelligence/machine learning, pharmacometricians may increasingly benefit from a...
5.
Nathoo N, Wu Y, Rogers J, Yong V, Dunn J
Mult Scler Relat Disord
. 2021 Jul;
54:103124.
PMID: 34243102
Background: Susceptibility weighted imaging (SWI) has detected veins in the center of white matter lesions and alterations in veins themselves in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). However,...
6.
Hamilton A, Forkert N, Yang R, Wu Y, Rogers J, Yong V, et al.
Sci Rep
. 2019 Jun;
9(1):8488.
PMID: 31186441
Atrophy has become a clinically relevant marker of progressive neurodegeneration in multiple sclerosis (MS). To better understand atrophy, mouse models that feature atrophy along with other aspects of MS are...
7.
Rogers J
CPT Pharmacometrics Syst Pharmacol
. 2019 Feb;
8(5):253-255.
PMID: 30762316
No abstract available.
8.
McCreary J, Rogers J, Forwell S
Int J MS Care
. 2018 Oct;
20(5):211-223.
PMID: 30374251
Background: To present the current knowledge on the characteristics, assessment, and treatment of upper limb intention tremor to inform and improve future intervention studies in patients with multiple sclerosis (MS),...
9.
Caprariello A, Rogers J, Morgan M, Hoghooghi V, Plemel J, Koebel A, et al.
Proc Natl Acad Sci U S A
. 2018 May;
115(21):5528-5533.
PMID: 29728463
Although immune attack against central nervous system (CNS) myelin is a central feature of multiple sclerosis (MS), its root cause is unresolved. In this report, we provide direct evidence that...
10.
Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy
Plemel J, Michaels N, Weishaupt N, Caprariello A, Keough M, Rogers J, et al.
Glia
. 2017 Oct;
66(2):327-347.
PMID: 29068088
For decades lysophosphatidylcholine (LPC, lysolecithin) has been used to induce demyelination, without a clear understanding of its mechanisms. LPC is an endogenous lysophospholipid so it may cause demyelination in certain...